

Image-based modelling of inhaler deposition during respiratory exacerbation

Josh Williams^a, Jari Kolehmainen^b, Steve Cunningham^c, Ali Ozel^{a,*}, Uwe Wolfram^{a,*}

^a*School of Engineering and Physical Sciences, Heriot-Watt University, Edinburgh, UK*

^b*Department of Chemical and Biological Engineering, Princeton University, Princeton, New Jersey, USA*

^c*Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK*

Abstract

For many of the one billion sufferers of respiratory diseases worldwide, managing their disease with inhalers improves their ability to breathe. Poor disease management and rising pollution can trigger exacerbations which require urgent relief. Higher drug deposition in the throat instead of the lungs limits the impact on patient symptoms. To optimise delivery to the lung, patient-specific computational studies of aerosol inhalation can be used. However in many studies, inhalation modelling does not represent an exacerbation, where the patient's breath is much faster and shorter. Here we compare differences in deposition of inhaler particles (10,4 µm) in the airways of a healthy male, female lung cancer and child cystic fibrosis patient. We aimed to evaluate deposition differences during an exacerbation compared to healthy breathing with image-based healthy and diseased patient models. We found that the ratio of drug in the lower to upper lobes was 35% larger during healthy breathing than an exacerbation. For smaller particles the upper airway deposition was similar in all patients, but local deposition hotspots differed in size, location and intensity. Our results identify that image-based airways must be used in respiratory modelling. Various inhalation profiles should be tested for optimal prediction of inhaler deposition.

Keywords: Aerosol deposition, Respiratory exacerbation, Patient-specific modelling, Drug dosimetry, Metered-dose inhaler, Computational fluid dynamics

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

*Corresponding authors share last authorship. Address: Heriot-Watt University, Edinburgh EH14 4AS, UK
Email addresses: a.ozel@hw.ac.uk (Ali Ozel), u.wolfram@hw.ac.uk (Uwe Wolfram)

25 **Highlights**

- Regional and local drug deposition was modelled in three patients during normal, sinusoidal inhalation and an exacerbation.
- Local drug deposition changes with airway shape and inhalation profile, even when regional deposition is similar.
- 30 • Image-based models were combined with highly-resolved particle tracking including particle contact and cohesion.
- Fluid model validated by comparing gas velocity field with in vitro experiments.

1. Introduction

More than one billion people worldwide suffer from asthma, cystic fibrosis, and other chronic respiratory diseases (The Global Asthma Network, 2018), many experiencing distress and anxiety due to restrictions to activities and limited productivity (Dockrell et al., 2007). These limitations are most prominent among the young and elderly (The Global Asthma Network, 2018). One of the largest contributors to the diseased population is asthma, which incurs an annual cost per patient of €1,700 and \$3,100 in Europe and the USA, respectively (Nunes et al., 2017) from direct cost of treatment and indirect costs such as work absence or decreased productivity (Katsaounou et al., 2018; Gruffydd-Jones et al., 2019). Similar impacts are induced from cystic fibrosis (Chevreul et al., 2015). Consistent treatment in alignment with disease management plans are recommended to minimise symptoms (Ring et al., 2015), but adherence is an issue in young patients (McQuaid et al., 2003) and many adults are purposely inconsistent to limit exposure to side-effects such as osteoporosis and cataracts (Dockrell et al., 2007). Even in adherent patients, efficiency of the metered-dose inhaler varies greatly across patients (Clark, 1995) as many (particularly children) experience difficulties in device technique (Usmani, 2019) due to the rapid spray of the drug. The issue of technique (patient breathing pattern and coordination with device actuation) and differences in lung structure are the main influences in drug delivery (Darquenne et al., 2016).

Optimisation of the medication deposition could be achieved through *in silico* analyses, by providing the clinician information on the local deposition and therapeutic outcome. One available deposition tool is the Multiple-Path Particle Dosimetry (MPPD) model (Anjilvel and Asgharian, 1995; Asgharian et al., 2001). However this calculates deposition of ambient particles (Borghardt et al., 2015), which does not mirror the physics of spray aerosol inhalation (Longest et al., 2008). This issue has been recognised and a commercial counterpart to predict deposition of pharmaceutical aerosols has been developed (Olsson and Bäckman, 2018). However, as the equations used are based on probabilistic 1D equations, similar to that of MPPD, complex fluid phenomena generated in the upper airways and particle interactions cannot be included. Comparisons between 1D models and computational particle-fluid dynamics (CPFD) deposition led Zhang et al. (2009) to observe significant differences in local deposition due to local flow features not captured in 1D models. Flow and particle

phenomena can be readily accounted for in CPFD by solving equations governing the transport of air and particles (e.g. see Sundaresan et al. (2018)). Flow can be solved in airways
65 extracted from medical images and particle properties can represent inhaler particles to produce patient-specific deposition analyses. But with the complexity of the flow regimes in the system creating demanding simulations and the massive number of respiratory patients, the benefit-to-cost of image-based modelling is an issue. Work exists interpreting pharmaceutical deposition differences in adult patients (Feng et al., 2018; van Holsbeke et al., 2018;
70 Poorbahrami and Oakes, 2019; Poorbahrami et al., 2019), but child deposition models are limited to idealised geometries (Das et al., 2018; Longest et al., 2006; Deng et al., 2018). Existing children-focused image-based deposition studies analyse the nasal cavity (Xi et al., 2011, 2012) or central airways (Oakes et al., 2018), which neglects the effect of turbulence generated in the mouth and throat. To move towards enhanced treatments for all ages, a
75 study considering the impact of the upper airways is needed. We begin this by comparison of deposition in the airways (from mouth to central airways) in a group of three patients, containing a child and two adults. This can allow simulation of flow created in the upper airways and provide understanding of how this affects deposition throughout the airways, across patients.

80 Results from these simulations are dependent on the inflow conditions, which here is based on the duration and strength of the patient's inhalation. Colasanti et al. (2004) showed the breathing profile of a patient with extremely obstructed airways, which differed in shape and magnitude from the sinusoidal inhalation waveform that is typically used in respiratory CPFD studies (Inthavong et al., 2010). A sinusoidal inhalation waveform is used by most
85 existing studies (Oakes et al., 2018; Inthavong et al., 2010; Naseri et al., 2017), which mimics a healthy patient's tidal breathing. The variation in flow patterns produced by these differences would therefore give a deposition analysis which may not represent the flow during bronchoconstriction, when a 'reliever' inhaler (bronchodilator) is used. Different breathing profiles have been utilised (Longest et al., 2012; Khajeh-Hosseini-Dalasm and Longest, 2015),
90 but these were used to represent techniques for different devices (dry-powder compared to metered-dose inhalers), not exacerbating and healthy breathing in a metered-dose inhaler. By applying different inflow conditions, one can understand changes in flow structure dur-

ing an exacerbation or another desired breathing situation. This knowledge would allow manufacturers to tailor inhaled therapeutics to ensure optimal dosage reaches the desired
95 site in the airways, and to provide clinicians and patients the tools with which to maximise inhalation technique during exacerbations.

In addition, existing MDI deposition research simplifies particle interactions, which includes treating particle-wall collision as complete sticking. This is a coarse approximation of dissipative lubrication forces between the particle and wall (Legendre et al., 2005; Holbrook
100 and Longest, 2013). To treat as fully sticking therefore neglects rebound and could overestimate deposition of high inertia particles. Furthermore, MDI studies often exclude van der Waals forces (Hamaker, 1937) which can cause small particles agglomerate, and become more inertial. If the increase in inertia is large enough, this can change particle trajectory or chance of rebound, which, in turn would cause early deposition. How these forces alter
105 deposition and compete against each other should be tested. Applying this to simulations made specific to a patient's airway structure under extreme and optimal breathing will further understanding of drug transport across different health states.

Therefore, we aimed to (i) evaluate the effect of patient-specific airway shape on drug deposition. To satisfy this we also aimed to (ii) identify the necessary physical effects to pro-
110 duce accurate models of the system (including the mass of drug simulated, van der Waals and particle-wall lubrication forces), and (iii) evaluate change in deposition during an exacerbation compared to healthy breathing.

2. Methods

To answer the research aims above, we evaluated changes in deposition produced by
115 the following variations. Parameters varied included the mass of drug simulated, particle cohesiveness, lubrication forces in particle wall-collisions, and deletion or saving of deposited particles from the system to mimic absorbing particles with mucus layer. The use of a healthy and exacerbation breathing profile (Colasanti et al., 2004) allowed for analysis of the reliever inhaler during an exacerbation. The effects of patient variation were then
120 analysed using this optimised modelling setup, through comparison under realistic inflow conditions in three patients.

2.1. Medical image processing

Three patients were studied retrospectively using computed tomography (CT) (detailed in Table 1). Use of these retrospective images was approved by Heriot-Watt University (ID: 2020-0500-1452). The surface file of the healthy patient's segmented airways was provided by the study of Banko et al. (2015). The patients had sufficient variation in age, gender and health status to gather an indication of the benefit of patient-specificity.

Table 1: Information of patients studied in this work. Although a small group, variations in gender, age and disease have been included.

Gender	Age	Illness	Voxel size [mm ³]	Source
Male	45–50	Healthy	$0.977 \times 0.977 \times 2.5$	Zhang et al. (2012), Banko et al. (2015)
Female	Unknown (adult)	Lung cancer	$0.977 \times 0.977 \times 3.0$	Yang et al. (2017) Yang et al. (2018) Clark et al. (2013)
Male	10–15	Cystic fibrosis	$0.5254 \times 0.5254 \times 1.0$	

Images were processed using 3D Slicer 4.10 (Fedorov et al., 2012). Images were pre-processed by applying isotropic spacing to account for the anisotropic resolution of CT scans (Table 1). For the cancer patient, voxel size was then reduced using a linear interpolation, creating a voxel size of ≈ 0.4 mm to allow extraction of smaller airways. This was also performed on the cystic fibrosis patient. To preserve edges of the airway while blurring lung tissue, an anisotropic diffusion filter was then applied (Duan et al., 2019). Parameters used were conductance 3, 5 iterations and step size of 0.06025. These were based on visual comparison of our segmentations produced from varying values of conductance used by Behnaz et al. (2010) and Sen et al. (2011).

Images were then segmented using a threshold-based region-growing approach to segment areas classified as air without leakage to the background air (Nardelli et al., 2015; Mayer et al., 2004; De Nunzio et al., 2011; Aykac et al., 2003). This semi-automatic process grows the segment from 'seeds' which are user declared points within each region, set separately for the airway and surrounding lung tissue. Once each region was grown, labels denoting leaked regions were found by overlaying the segmentation on the scan. Leaked regions were then labelled as airway and the region was grown again until the scan was observed to be acceptable quality. This process was applied to the external airways, right and




Figure 1: Segmented airway trees of patients included in the study. The airways are presented from left to right as (a) the healthy, male adult (Banko et al., 2015), (b) the adult, female lung cancer patient (Yang et al., 2017, 2018; Clark et al., 2013), and (c,d) the male child cystic fibrosis patient. The child patient has (c) constricted throat added from the cancer patient (b), and (d) has a dilated throat taken from the healthy patient (a). Areas within the dashed box have been artificially added due to available images not including this region.

145 left lungs separately due to variations in the airway image density in each region (Nardelli et al., 2015). This allowed segmentation to a depth ranging from the fourth to sixth bifurcation level (G4 – G6, Figure 1).

Some of the upper airways were not included in the CT data, we have found this to be common in most clinical CT scans. To account for this we merged the oral cavity of the healthy patient to the throat of the lung cancer patient. This region was then extracted, 150 scaled and joined to the trachea of the cystic fibrosis patient to complete the missing regions. Scaling was performed such that the intersection of the new and existing regions matched in diameter (resulting in a scaling of 0.8 for the added region). This was later repeated using the throat of healthy patient, after being advised such a narrow, obstructed throat is not 155 characteristic of cystic fibrosis, and likely unique to the cancer patient. The regions which were artificially added are shown graphically in Figure 1 within the dashed box. These excluded regions are of large importance in inhaler simulations as a large portion of the dosage is lost within this part of the airway and the turbulence created here is cascaded through the trachea and main bronchus (Banko et al., 2015).

160 2.2. Mathematical modelling

Here we present the mathematical relations used to determine the physical factors included in our model of the system. We provide the equations governing the fluid and particle solvers in Appendix A. Briefly, particle transport was solved by the discrete element method (DEM) using the particle simulator LIGGGHTS (Kloss and Goniva, 2011).
165 This tracks each individual particle's trajectory by integrating Newton's equations of motion in time (Verlet, 1967). Particle collisions were modelled as a linear spring-dashpot system (Cundall and Strack, 1979). Fluid transport through the airways was solved by the volume-filtered mass and momentum conservation equations (Anderson and Jackson, 1967; Capecelatro and Desjardins, 2013) implemented in OpenFOAM v2.2 (Weller et al., 1998).
170 Particle and fluid phases were coupled through a version of the CFDEMcoupling platform (Kloss et al., 2012) modified to benefit from faster two-way coupling by Ozel et al. (2016).

Filtering the fluid transport equations creates unresolved stresses. In our simulations, we consider residual stresses from volume-filtering of fluid velocity fluctuations (\mathbf{R}_u) below the
175 cell size, Δ . \mathbf{R}_u is dependent upon the eddy viscosity (μ_t), a term representing turbulence dissipation into the smaller, unresolved scales. Eddy viscosity is modelled using a dynamic Smagorinsky model (Germano et al., 1991; Lilly, 1992). This uses a second filter with width 2Δ to sample the smallest resolved scales, and calculate the local Smagorinsky constant C_S . Using the classic Smagorinsky (1963) model requires a global C_S which makes the model
180 unable to represent a range of flow (Germano et al., 1991), such as the laminar-turbulent-laminar transitions in the airways.

We compute drag forces acting on particles using Beetstra et al. (2007)'s model for monodisperse particles. This drag model is based on the particle's Reynolds number, Re_p , given as

$$Re_p = \frac{\rho_f |\mathbf{v}_r| d_p}{\mu_f}, \quad (1)$$

185 where $|\mathbf{v}_r|$ is the magnitude of the relative velocity vector between gas and particle velocities, d_p is the particle diameter, μ_f is the molecular viscosity of the gas phase.

As well as the particle Reynolds number, we also characterise our system through the particle's Stokes number, St . This is the ratio of particle timescale (τ_p) to fluid timescale (τ_f),

given by

$$St = \frac{\tau_p}{\tau_f} = \frac{\rho_p d_p^2 u}{18\mu_f D} \quad (2)$$

where D is the inlet diameter, and we take u as the peak cross-sectional velocity at the inlet Kleinstreuer and Zhang (2003). This gives $St \gg 1$ when particles have high inertia and are not perturbed by fluid fluctuations. Conversely, when $St \ll 1$ the particles follow the fluid streamlines closely and will have lower deposition in the upper airways. In gas-solid flows, when $St \approx 1$ particles will concentrate in clusters of low fluid vorticity (Squires and Eaton, 1991).

Again, due to the particle's small size, particle-particle cohesion from van der Waals forces may influence deposition. Particle attractive energy due to van der Waals force is determined by the material's Hamaker constant, A (Hamaker, 1937). For a linear sliding-dashpot particle-particle collision model, it is not affordable to use a realistic stiffness due to limitation of very small time-step. Therefore, to permit a larger timestep, the elastic properties of the particles were softened. Therefore the real stiffness (k_R) is reduced to a soft stiffness (k_S), and the Hamaker constant is amended by the relationship $A^S = A^R(k_S/k_R)^{1/2}$ using the model of Gu et al. (2016a). This reduction of real particle stiffness (k_R) to a softer stiffness (k_S) has negligible effect on fluid hydrodynamics and particle cohesion (Gu et al., 2016a; Ozel et al., 2017). To determine A , which is not given in literature for the metered-dose inhaler propellant HFA-134A, we evaluate deposition at three Bond numbers, Bo . Bo is provided by Ozel et al. (2017) as

$$Bo = \frac{F_{vdw}^{\max}}{m_p |\mathbf{g}|} = \frac{A d_p}{24(s_{\min}^R)^2 m_p |\mathbf{g}|}, \quad (3)$$

where F_{vdw}^{\max} is the maximum van der Waals force magnitude occurring when $s = s_{\min}^R$ (the minimum separation distance for a particle at its real stiffness). This was varied three orders of magnitude, $Bo = 10, 100, 1000$ which was sufficient variation to interpret cohesive differences. This magnitude of variation was chosen as it showed changes in deposition without running a large amount of simulations at finer Bo intervals. This also gave A at $Bo = 1000$ of the same order of magnitude ($A = 10^{-20}$ J) to drug particles in the inhaler propellant HFA-227 (Engstrom et al., 2009).

215 Further complexities arise when considering particle-wall interactions. This is widely treated as a fully plastic collision due to the presence of a respiratory mucus layer (Miyawaki et al., 2012; Zhang et al., 2018; Chen et al., 2012; Naseri et al., 2017). This may occur due to lubrication interactions, which have been experimentally shown to damp collision forces (Legendre et al., 2005) due to the formation of a thin interfacial film during contact. This relation
220 has been shown to follow the expression

$$e_{iw} = \frac{v_R}{v_C} = \exp\left(-\frac{35}{St_{coll}}\right), \quad (4)$$

for solid particles (Legendre et al., 2005). Here, subscripts $(.)_R$ and $(.)_C$ are the rebound and pre-collision velocities, respectively, v_T is the velocity of the particle before collision and the collision Stoke's number (Legendre et al., 2006) is given as

$$St_{coll} = \frac{(\rho_p + \rho_f)d_p v_T}{9\mu_f}. \quad (5)$$

The effective restitution coefficient, e , follows a sigmoid trend when plotted against St_{coll} ,
225 with $St_{coll} < 10$ creating a plastic collision similar to that approximated in modelling of particle-mucus layer interactions. We implemented this relationship to model particle-wall contact force, then when later deleting or freezing deposited particles, use it to determine the cutoff. We use this to model particle-mucus layer collision instead of the typical 'sticking' condition (Miyawaki et al., 2012; Zhang et al., 2018; Chen et al., 2012; Naseri et al., 2017). This
230 allows potential for particle rebound after impacting the wall. Therefore, as the particle-wall interaction is better represented, deposition is not over-estimated.

2.3. Simulation configuration

2.3.1. Fluid-phase Simulations

We first validated the fluid phase by comparison to a published experimental study
235 (Banko et al., 2015). The study observed water flow in a 3D printed hollow cast of an adult male patient's airways (Figure 1a) at a Reynolds number representative of heavy breathing ($Re_{inlet} = \rho_f U D_{inlet} / \mu_f = 3600$ corresponding to $Q = 1$ L/s). First we simulated water flow through the airways to validate our fluid solver. We then simulated airflow at the same Re . Single-phase (water) transport through lung airways was simulated using OpenFOAM

240 solver pimpleFoam, then when simulating air we used the particle-carrier phase, or namely CPFD, solver with no particles. We investigated the effect of mesh resolution on the results by simulating two uniform, hexahedral meshes (5×10^5 and 10^6 cells). We used the mesh with 10^6 cells for all simulations after the mesh sensitivity study. As interaction between the gas and particle phases (namely, drag) is dependent on the size of Δ relative to d_p (Agrawal et al., 2001), we made the size of cell in our 10^6 mesh $\Delta = 500 \mu\text{m} = 50d_p$ to minimise drag overestimation. This is of the same order of magnitude as coarse-fluid grid simulations performed by Radl and Sundaresan (2014). We kept grid size consistent with our first particle size tested (at $d_p = 10 \mu\text{m}$, $\Delta = 500 \mu\text{m}$) throughout the study to minimise excessive computation time when later reducing particle size.

250 We applied an inlet condition which added random components to the inlet flow velocity (Sagaut, 2006) to account for upstream fluctuations in the experimental apparatus. This was used with an inflow velocity of $u_{\text{water}} = 0.167 \text{ m/s}$ and $u_{\text{air}} = 2.677 \text{ m/s}$, with a no-slip condition at the wall. Outlets had a uniform, fixed pressure applied to each bronchi. Although not truly representative of outflow conditions within the lung, a uniform outlet condition has been shown to be acceptable when the bronchi are extended a few diameters in the axial direction to eliminate secondary flow effects (Zhang et al., 2012). This has been shown to resemble more advanced outlet conditions which consider compliance of the lung (Ma and Lutchen, 2006).

2.3.2. Aerosol transport simulations

260 In multiphase simulations we coupled the single-phase approach above to the DEM solver to track monodisperse particles of $d_p = 10$ and $4 \mu\text{m}$. Particles are classed as deposited and deleted from the system when impacting the wall with low inertia ($St_{\text{coll}} < 20$). As CT scan resolution only permitted segmentation to approximately the sixth bifurcation level (Figure 1), particles reaching the end of the bronchial path were classified as reaching the distal airways and deleted. As we only model a limited amount of bifurcation levels (between four to six), this is a coarse approximation of downstream behaviour and dosage reaching the small airways.

The dosage was released over a period of $t = 0.1 \text{ s}$ (Ju et al., 2010). The particle motion was discretised in time based on calculation of the collision time of the particles, $t_{\text{DEM}} =$

Table 2: Flow properties with model parameters used in simulations, as well as dimensionless quantities varied. Three separate volume fractions were used to observe sensitivity to the number of dosage simulated. Three Bond numbers were simulated to determine the effect of van der Waals forces. Finally, particle-wall lubrication forces were included by comparing a collision with fixed restitution coefficient e and one dependent on St_{coll} .

Flow property & Parameter	Value	Source
$\rho_g / \text{kg/m}^3$	1.2	Robinson et al. (2007)
$\mu_g / \text{Pa} \cdot \text{s}$	1.8×10^{-5}	
$d_p / \mu\text{m}$	10, 4	Kleinstreuer and Zhang (2010)
$\rho_p / \text{kg/m}^3$	1207	Mexichem (n.d.)
$v_{p,in} / \text{m/s}$	30	Newman (2005)
$k_S / \text{N/m}$	100	Gu et al. (2016a)
k_R / k_S	1000	Chen et al. (2012)
μ_p	0.5	Gu et al. (2019)
e_{ij}	0.9	Gu et al. (2019)
e_{iw}	$0.9, e_{iw}(St_{coll})$	Legendre et al. (2005)
Characteristic Quantities	Value (corresponding physical quantities)	
ϕ_{avg}	$7.4 \times 10^{-8}, 7.4 \times 10^{-7}, 3.7 \times 10^{-6}$ ($N_p = 20 \times 10^3, 200 \times 10^3, 10^6$ at $d_p = 10 \mu\text{m}$)	
St	0.05, 0.009 ($d_p [\mu\text{m}] = 10, 4$)	
Re_p	18.5	
Re_{inlet}	3600	
Bo_p	10, 100, 1000 ($A^R [\text{J}] = 1.5 \times 10^{-22}, 1.5 \times 10^{-21}, 1.5 \times 10^{-20}$)	

270 $\pi(2k_n/m - \gamma_n^2/4)^{-1/2}/7$ (Gu et al., 2016a). The van der Waals stiffness scaling (Gu et al., 2016a) was set to $A^S = A^R(k_S/k_R)^{1/2} = A^R/31.6$. Particle lubrication force was modelled using mucus layer viscosity ranging from $\mu_{mucus} = 0.026 - 0.05 \text{ Pa} \cdot \text{s}$ dependent on disease (Rubin, 2007) and a density of $\rho_{mucus} = 1000 \text{ kg/m}^3$ as it is largely made up of water in the upper airways (Olsson et al., 2011). Parameters used are summarised in Table 2. Simulations were performed on high-performance computers ROCKS of Heriot-Watt University and EDDIE of the University of Edinburgh high-performance computers using 28 – 64 CPU cores. Simulations with $10 \mu\text{m}$ particles took 2-6 weeks. Simulations with $4 \mu\text{m}$ particles took 4-16 weeks.

280 Once the optimal parameters were determined, a time-varying inlet condition was implemented to represent a real breathing cycle (Figure 2). For this we used data provided by Colasanti et al. (2004) whom analysed the breathing profile of patients suffering from COPD and cystic fibrosis with extreme airway obstructions. Colasanti et al. (2004) also presented




Figure 2: Breathing profiles for healthy and diseased patients used in this study (Colasanti et al., 2004). Positive flow rate represents inhalation and negative represents exhalation. A standard sinusoidal breathing profile is shown for comparison. Differences between healthy and simplified breathing conditions are minor, but the exacerbation profile reaches a higher peak inhalation at a faster rate. Adapted from Williams et al. (2021) with permission of RDD Online LLC.

a healthy patient's inhalation profile. The magnitude of the child's inhalation velocity was lowered by half, based on inhalation velocities used in a similar study (Longest et al., 2006).

To compare the effect of inhalation waveform, all patients were simulated using both the healthy and exacerbation profile (Figure 2) using $10\mu\text{m}$ and $4\mu\text{m}$ particles. To evaluate the effect of the missing throat and mouth of the cystic fibrosis patient, we model this patient using the mouth and throat of the healthy patient and cancer patient.

2.4. Deposition evaluation

Particle deposition was analysed by regional groupings of the mouth, throat, trachea, main bronchus and bronchi within each lobe of the lung (as used by Asgharian et al. (2001) and van Holsbeke et al. (2018)). We also provided results grouped into external airways (mouth to end of first branch), and internal airways (airways within the lungs). We use this to evaluate preferential deposition within airways' different regions.

In contrast to the fully plastic ('sticking') particle-wall condition used in literature, our particles may rebound as we resolve collisions over multiple timesteps. We classed particles that had low inertia prior to impacting the wall as deposited. This inertia was based on Equation (4). We compared results where these particles were kept active in the domain to interact with floating particles, or where we simply deleted them. The difference in these

300 was found to be minimal (under 5% in all regions). Therefore we opted to delete them due to superior computational efficiency (reached 0.1 s physical time in 30% faster clock time).

Due to the particle's ability to slide along the wall in our parameter study simulations, when stuck it would not be completely stationary. To extract particles on the wall for comparison to our sticking condition, deposition was defined when the particle velocity was
305 sufficiently below that of the free-stream ($v = 0.01$ m/s, 900 times less than gas velocity in the throat). This velocity cutoff was found through observed comparison of velocities of slowly floating and deposited sliding particles. Particles that were below this threshold were classed as deposited deleted during post-processing.

Due to the locally-acting nature of inhalers (Lu et al., 2015), it is important to understand therapeutic distribution and dosage experienced by the patient based on deposition
310 concentration (Solomon et al., 2012). We interpreted this through the dosimetry measure of deposition enhancement factor (DEF) (Balashazy et al., 1999; Longest et al., 2006). We calculate this using the number of particles deposited within a fixed distance (1 mm, area $A_{conc} = \pi (1 \text{ mm})^2$) of the central point of each wall face. This distance was based on that
315 used by Dong et al. (2019). Other studies have used much narrower radii (Longest et al., 2006; Xi et al., 2012), but using this wider radius can account for particle translocation during the time between deposition and absorption. This is made relative to the global deposition by

$$\text{DEF} = \frac{\text{Deposition concentration within } A_{conc} / A_{conc}}{\text{Total deposited particles} / \text{Total airway surface area}}. \quad (6)$$

We use this instead of the sum of the deposition efficiencies as the defined areas may overlap, and this therefore prevents particles being counted multiple times towards the global
320 average.

3. Results

3.1. Validation of Carrier-phase Simulations

As discussed before, dynamics of low-inertia aerosols (as $St < 1$) is significantly altered
325 by carrier-phase flow field. Hence, we first focused on carrier-phase flowfield validation. Turbulence induced in the upper airways is the foundation of the flow structure, creating secondary flows which are responsible for deposition in the trachea (Jin et al., 2007; Kleinstreuer and Zhang, 2010). Therefore, the upper airways are a suitable region for the val-




Figure 3: Comparison of single-phase flow in the upper airways to demonstrate mesh independence and independence of water and gas simulations at equal Reynolds numbers. (a) Location of shown contour (red) in domain (Banko et al., 2015, Figure 5), with arrows indicating direction of view for comparison of the normalised velocity magnitude contours of: (b) experimentally obtained water flow (Banko et al., 2015, Figure 5), and numerically obtained water flow on a (c) moderate grid density and (d) fine grid. (e) Numerically obtained airflow on a fine grid.

idation (Figure 3). All results have been normalised by the mean velocity in the trachea
 330 ($V_{T,\text{water}} = 0.22 \text{ m/s}$ and $V_{T,\text{air}} = 3.51 \text{ m/s}$). The strong jet of flow formed at the throat matches the experimental study well in magnitude and structure, capturing the recirculation zones as the throat expands well. Banko et al. (2015) gave the bulk (area-averaged) velocity U relative to V_T as 1.73 in the glottis, compared to our value of 1.77, producing a 2.3% relative error.

335 The resemblance in flow structure continues in the lower airways, from both coronal and axial views as given in Figure 4 (see Banko et al. (2015) for further comparison). The slight separation seen at the left bronchus (right side of (a)) agrees well with the experimental data. Contours in the axial region (shown in (b)) agree well in shape, accurately capturing recirculation and asymmetrical flow. However, velocity vectors shown in C-C' and D-D' differ
 340 from the published results. This likely stems from differences in time-averaging of such a sensitive parameter in highly unsteady flow. Vectors in B-B' and E-E' match the experimental data well. Qualitatively comparing numerical and experimental velocity fields (Banko et al., 2015) verifies that the single-phase flow configuration is suitable to capture the flow patterns present. To quantitatively validate the solver, we compare the relative bulk velocity
 345 (U/V_T). Banko et al. (2015) gave this as 1.03 in the trachea, matching our solver exactly. In the left main bronchus, we had a value of 0.67, differing from the experimental results of 0.70 by 4.3%. In the right bronchus the numerical and experimental relative bulk velocity was $U/V_T = 0.88$ and 0.87, respectively (relative error 1.2%). These relative bulk velocity




Figure 4: Time-averaged water velocity field at the first bifurcation, structured the same as presented in experimental study (Banko et al., 2015, Figure 9) for ease of comparison. (a) Normalised velocity magnitude at the first bifurcation from the coronal view, and (b) the velocity magnitude normal to the flow at various axial cuts shown in (a).

comparisons at key cross sections of the airway validate that our solver can reproduce the
 350 *in vitro* respiratory velocimetry measurements of Banko et al. (2015) to an error below 5%.

3.2. Effect of parameter variations

To model inhaler inhalation the simulation's sensitivity to the dosage simulated, van der Waals forces and particle-wall lubrication forces were evaluated. The influence of each of these were examined by their influence on dosage deposition.

As physical parameters were varied, one can observe that deposition distinctions are
 355 mostly minor, as deposition changes across each lobe were all under 1.5% of the total dosage (Figure 5). When increasing the number of particles the only change came at $N_p = 1,000,000$ (Figure 5c), as the throat deposition rose by 2%, in all other regions the difference was less than 1%. For this reason 200,000 particles was chosen for the remaining simulations to re-
 360 duce simulation times. Although we have purposely underestimated N_p , the number of particles should not be chosen arbitrarily. Instead the sensitivity of the model to this parameter should be included as an early set of simulations in all studies where the true payload cannot be simulated. When including particle cohesion and particle-wall lubrication (Figure 5h,i), deposition in the throat due to particle-wall lubrication forces rose by 13% of the
 365 total dosage. This effect is reduced by 4% when modelling van der Waals forces, likely explained by the agglomeration of particles providing additional inertia (increasing St_{coll}), thus reducing the energy lost due to lubrication. This also explains why minimal changes are observed in Figure 5(d – f).




Figure 5: Dosage deposited within each region of the airways with time, for the parameter variations given in Table 2. (a, b, c) Compares deposition with simulation of various particle numbers. Remaining rows present results using $N_p = 200,000$. (d, e, f) Shows deposition with variation of the van der Waals force in relation to the dimensionless quantity Bo . (g, h, i) Compares deposition with inclusion of lubrication forces and van der Waals particle-particle interactions. Each line is representative of an airway region, corresponding to the coloured airway included in the left-most plot of each row. An additional grey, dashed line is included to show the rate at which particles enter the system from the inhaler.

The parameters taken forward to evaluate deposition variance in the diseased patients were: a dosage of $0.126 \mu\text{g}$ ($N_p = 200,000$ at $d_p = 10 \mu\text{m}$), a Bond number of 1000, and particle-wall lubrication forces. Time-varying breathing profiles were also applied (Figure 2). Although particle count is underestimated, the error is within 5%, for a computation time reduction of 62% ($N_p = 200,000$ took three weeks, whereas $N_p = 1,000,000$ took eight). These parameters were considered to model the particle behaviour accurately, with a small sacrifice made to reduce computational cost.

3.3. Inter-patient variation

To evaluate the influence of airway shape on deposition we compare regional deposition for each patient in Figure 6. To understand the influence of breathing profile we also include the healthy patient with a healthy inhalation in Figure 6. Due to the dominance of upper airway deposition, it is difficult to visualise differences in central airway deposition. When viewing deposition as a logarithm the behaviour in the lobes can be analysed with greater ease (Figure 6). Across the five simulations the dosage was mainly deposited in the external airways (Figure 6), as deposition here was always greater than half of the payload. Given the size of the particles compared to the distribution used in inhalers, a large deposit here was expected. For the most constricted external airways (Figure 6c, d) the deposition fraction was 0.95 and 0.85, respectively. Deposition in the cystic fibrosis (dilated throat) patient's trachea dropped by 13.4% relative to the total dose (Figure 6d, e). There is an external airway deposition rise of 1.9, 1.7 and 1.5 times when comparing the healthy patient with exacerbation breathing against the cancer and cystic fibrosis patients (constricted and dilated throats), respectively.

We compared deposition in the external airways for the healthy patient, lung cancer patient and cystic fibrosis (with dilated throat) at $d_p = 10$ and $4\mu\text{m}$ (Figure 7a, b). With a healthy breathing profile and $10\mu\text{m}$ particles (Figure 7a), external airway drug deposition lowers by 23% of the dose for the healthy patient, relative to the deposition with rapid breathing. The external airway deposition is lowered by 43% relative to the deposition during an exacerbation for the cystic fibrosis patient (Figure 7a and Supplementary Video). Similarly, the deposition is lowered by 48% for the lung cancer patient (Figure 7a), relative to during an exacerbation. For the $4\mu\text{m}$ particles (Figure 7b), the upper airway deposition did not change for the cystic fibrosis and lung cancer patients when comparing deposition under the two different inhalations. Upper airway deposition in the healthy patient lowered from 30% of the total dose to 22% when modelling the healthy inhalation.

To compare the influence of airway shape and inhalation profile on the drug reaching the deep lung, we show the fraction of the total dose that exits the outlets of our CT-domain to the deep lung (Figure 7c, d). Reducing the particle size increased the dosage reaching the deep lung by 15 - 49% of the total dose across the three patients (Figure 7d). The largest




Figure 6: Comparison of regional deposited particles in three diseased model airways throughout a breathing cycle (Figure 2). Deposition is shown on a log scale to allow closer analysis of lobar deposits. Time has been normalised and patient illnesses described each plot. Line colours correspond to region in the coloured, generic airway tree on the left. Rate of particle injection to the domain given by the grey, dashed line.

increase (49% of the total dose) was in the lung cancer patient with the exacerbation breathing profile. In the 10 μm simulations, the dose reaching the deep lung increased by between 16 - 32% of the total payload (25% mean) for a healthy breathing profile compared to the exacerbation breathing profile (Figure 7c). The increase of 4 μm particles reaching the deep
410 lung with a healthy breathing profile was 3.3 - 9.6% (7% mean) of the total dose (Figure 7d).

As particles are known to distribute asymmetrically across the lungs (Lambert et al., 2011), we compared the ratio of particles in the right lung to left lung from Figure 7c and d. We also compared the ratio of drug in the upper and lower lobes. The right to left lung ratio was 1.04 and 0.96 in the healthy patient during a healthy inhalation for 10 and 4 μm
415 particles, respectively. In the cystic fibrosis patient during a healthy inhalation, the right to left lung ratio was 0.89 and 1.05 for 10 and 4 μm particles. During an exacerbation, the right to left lung ratio was 1.09 for both sets of particles. The drug distribution was most asymmetric for the lung cancer patient where the right to left lung ratio ranged from 2.29 to 5.62. The ratio particles in the lower lobes to upper lobes (neglecting the right middle lobe)
420 ranged from 1.08 in the lung cancer patient (exacerbation, $d_p = 4 \mu\text{m}$) to 3.31 in the cystic fibrosis patient (healthy inhalation, $d_p = 4 \mu\text{m}$) with a mean value of 2.04. On average the lower to upper ratio was 38% larger with the healthy breathing profile than the exacerbation for $d_p = 4 \mu\text{m}$ and 22% larger for $d_p = 10 \mu\text{m}$ (mean for all d_p is 35%). The asymmetry of drug distributed in the lobes can be seen for the 10 μm particles in the cystic fibrosis patient
425 with both inhalations in the Supplementary Video.

3.4. Dosimetry assessment

To evaluate local changes in deposition due to airway shape and inhalation profile, we compare the DEF for 10 μm particles (Figure 8). All simulations featured hotspots in mouth and throat which ranged from a maximum value of 116 for the lung cancer patient with a
430 healthy inhalation to 430 for the cystic fibrosis patient during an exacerbation. The maximum DEF in the bronchial airways of the healthy patient and cystic fibrosis patient was 20 during a modelled exacerbation and 40 during a healthy inhalation (increased by a factor of 2). Similarly, the maximum DEF in the lung cancer patient's bronchial airways increased from 3 during a modelled exacerbation to 45 during a healthy inhalation (increased by a
435 factor of 15).




Figure 7: Comparison of breathing profiles for 10µm, and 4µm particles. The top row compares external airway deposition (mouth to first bifurcation). The bottom row compares lobar distribution of drug exiting the domain outlets to reach the deep lung. Line style is consistent with each patient. Black lines denote deposition with an exacerbation breathing profile and blue lines denote deposition with a healthy breathing profile. Solid markers correspond to drug reaching the deep lung with an exacerbation breathing profile and hollow markers correspond to a healthy breathing profile. Adapted from Williams et al. (2021) with permission of RDD Online LLC.

During an exacerbation the 4µm particles are more uniformly dispersed than during a healthy inhalation (Figure 9). The maximum DEF in the bronchial airways increased from 44 during an exacerbation to 68 during a healthy inhalation in the cystic fibrosis patient (56%

increase). Similarly, the maximum DEF in the lung cancer patient's bronchial airways in-
440 creased from 33 during an exacerbation to 46 during a healthy inhalation (43% increase). The
maximum DEF increased from 32 during an exacerbation to 91 during a healthy inhalation
in the healthy patient's bronchial airways (190% increase). The airway surface area with a
DEF value of at least one ($DEF \geq 1$) increased by 89% in the cystic fibrosis patient in the
4 μm simulations compared to the 10 μm simulations. This surface area increased by 113%
445 for the lung cancer patient compared to the 10 μm simulations.

4. Discussion

In this study we aimed to evaluate deposition in patient-specific models during the rapid
breathing of an exacerbation, compared to during healthy breathing. This allowed the in-
vestigation to consider 'reliever' inhalers. By investigating this in a small, diverse patient
450 group we found patient-specific domains to be a necessity in future studies. For large par-
ticles (10 μm), there was a significant change in upper airway deposition with airway shape
and breathing profile. Small particles (4 μm) showed less sensitivity to total upper airway
deposition for all airway shapes and breathing profiles. This shows that small particles are
optimal for improving drug penetration to the deep lung during exacerbation. Local depo-
455 sition concentration (DEF) varied for all particle sizes, airway shapes and breathing profiles,
even in cases with identical regional deposition. Therefore, we recommend that patient-
specific models should be used to determine local concentration as this is a main driver of
clinical outcome.

We used highly-resolved particle tracking (DEM) to allow us to include cohesive and
460 collision forces. This was as cohesive van der Waals forces have been known to influence
the transport of micro-scale particles (Gu et al., 2016a). Soft-sphere (treating particles as de-
formable) deposition studies have been implemented before but only to observe dynamics
in simplified airways (Chen et al., 2012; Wang et al., 2017). We conclude that the computa-
tional cost of DEM is too large to be feasible for further study in broad patient populations
465 with varying inhalation parameters and drug properties (particularly smaller particles). The
results in Figure 5 suggest that cohesive and collision forces are of insignificance and may
be replaced by some stochastic collision tracking model such as that of van Wachem et al.
(2020). However, the computational cost of DEM also limited the dosage that could be mod-




Figure 8: Concentration of $10\ \mu\text{m}$ drug particle deposited on the airway wall of each model, normalised by total global deposition (DEF, Equation (6)). Hotspots visualised from the front (first and third columns) and rear (second and fourth columns) of each model. The maximum value (DEF = 100), describes an area with a drug concentration 100 times greater than the mean DEF of 1. Dosage is most concentrated in the throat as shown in Figure 6.




Figure 9: Concentration of 4 μm drug particle deposited on the airway wall of each model, normalised by total global deposition (DEF, Equation (6)). Hotspots visualised from the front (first and third columns) and rear (second and fourth columns) of each model. The maximum value (DEF = 100), describes an area with a drug concentration 100 times greater than the mean DEF of 1. Dosage is most concentrated in the throat as shown in Figure 6. Adapted from Williams et al. (2021) with permission of RDD Online LLC.

elled to 0.1 μg , which is 100 – 1000 \times less than a realistic dosage ($\approx 100 \mu\text{g}$). In reality, the
470 effects of cohesive and collision forces may be more influential as the particles will be more
densely concentrated. Also any effect of collision and cohesion will increase in juvenile pa-
tients due to their small airways creating a denser particle packing during inhalation. As
suggested by Islam et al. (2020) the effect of particle-particle interactions should be inves-
tigated across many cases to understand their influence on respiratory drug delivery, but
475 our study has provided a first step towards this. To use modelling to inform patient treat-
ments an understanding of different particle forces and their change with drug properties is
important.

Dosimetry analysis across the patients show noticeable differences in deposition in the
trachea (Figures 8 and 9), attributable to transitioning from the fast-flowing, constricted
480 throat to the expanding and curved trachea, of the cystic fibrosis and cancer patients. This
agrees with single-phase simulations of Wei et al. (2017) that found flow to vary with orien-
tation, as well as Bates et al. (2016) who showed the effect of pathological trachea curvature
on gas pressure and energy loss. Also the change in relative orientation of the trachea to
gravity present an additional factor to deposition changes. The healthy inhalation creates
485 deposition hotspots primarily at the bifurcation points (Figures 8 and 9). This occurs as the
effect of particle drift towards the wall of the trachea (turbophoresis) is naturally weaker in
a lower Reynolds number flow (Bernardini, 2014), which makes particle deposits mainly at
bifurcation points due to inertial impact (Zhang et al., 2018). However, the deposition of
4 μm was generally more uniformly dispersed on the airway wall during an exacerbation,
490 than during a healthy inhalation (Figure 9). This occurs as the small particles have low in-
ertia and are more influenced by turbulent secondary flows. As drug concentration across
the airway surface is important in its dissolution into the tissue (Solomon et al., 2012), this
provides a deeper understanding of the drug's absorption than a simple deposition analy-
sis. These results could be input to a model of the particle's interaction with the tissue at
495 smaller scales, as has been done by Olsson and Bäckman (2018) using 1D deposition data.
Using CPFD for this could further inform clinicians in comparing potential treatment and
delivery techniques for a patient.

When observing intra-patient drug delivery, the results presented show an uneven distribution across the lobes. There is a clear favour in transport to the lower lobes of the lung (Figure 7c, d). This is similar to observations made by Lambert et al. (2011), who used a single constant inlet velocity. However, our results extend this by showing that the number of particles in the lower lobes increases during a normal inhalation compared to an exacerbation. Patient-specific models could be used to attain a balanced dosage distribution, or target a specific region. This could allow for improved symptom relief through inhaler design informed by knowledge of regions sensitive to local inflammation (Barbu et al., 2011), allowing for more efficient devices. Additionally, cancerous regions of the lung could be targeted for chemotherapy using nebulisers (Tatsumura et al., 1993; Kleinstreuer and Zhang, 2003; Kleinstreuer et al., 2007). Clinicians could therefore predict and tailor the chemotherapeutic agent delivery through patient-specific CPFD models to minimise radiation reaching undesired areas of the lung. As a course of chemotherapeutic treatment is given over a period of around three weeks (Wittgen et al., 2007), this fits well with a high accuracy, time-consuming modelling method such as CFD-DEM.

Limitations of this study included the absence of imaging data available for the throat and mouth of the child, meaning this region was taken from the other patients and scaled. This of course limits the specificity of the main deposition site. However by simulating with the two available throat geometries merged to the child's trachea we can see that the deposition in the mouth and throat is unaffected (only changing 1%). The only differences are observed downstream in trachea deposition (Figure 6). Therefore, to neglect this region completely would harm the accuracy of the results downstream as flow generated in the upper airways heavily impacts downstream behaviour of both the gas and the particles (Figure 4). However, adding this region from adult patient to a child does not take into account the maturational effects of adolescence on the airway, which may impact deposition here. In future studies, images containing the mouth and throat are needed to ensure this important section is patient-specific.

An additional limitation is that patients lying down in scans may have slightly different airway shape and orientation when standing or sitting upright (Jan et al., 1994), as is a typical posture when taking inhalers. If using image-based CPFD to recommend treatments, the

patient images should be consistent with their typical posture when using their treatment where possible.

Only modelling the small number of airway bifurcation levels visible in the CT scan limits the model to only providing deposition information about the upper and central airways. To understand drug delivery in the smaller more distal airways the particles ‘exiting’ from our model’s outlets could be coupled to analytical 1D models (Kuprat et al., 2020; Koullapis et al., 2019). These models predict deposition based on particle size, estimated airway length and diameter, and flow rate. This would allow for a coarse prediction of drug delivery and efficacy in the targeted small airways.

Assumptions included the simulation of a uniform particle distribution. A uniform distribution is commonly used to research aerosol physics experimentally (Usmani et al., 2005, 2003), although does not directly represent the varying size distribution of inhaler particles (Dolovich, 1991). This is due to the small range of particle sizes (geometric standard deviation below two (Mitchell et al., 2003)) in a real device, meaning $St < 1$ in all cases, therefore the particles will exhibit high sensitivity to flow changes in both polydisperse and monodisperse flows. Deposition results should not be appreciably different as no transport characteristics are changed by this approximation. This allowed patient morphology differences to be evaluated in a simpler manner, without sacrificing accuracy.

Our simulations did not account for the effect of turbulent dispersion on particle transport. We used the interpolated fluid velocity to calculate the drag force acting on a particle, which neglects the influence of subgrid fluctuations in the motion of the gas phase. The low inertia of aerosol particles ($St \ll 1$) means that they are sensitive to small changes in the gas velocity. Filtering out these subgrid fluctuations has been shown to alter inertial particle ($St \geq 1$) segregation towards the wall and the resultant deposition in simple geometries such as channel flow (Marchioli et al., 2008). Using a stochastic model for the instantaneous velocity of fluid ‘seen’ by the particle has been shown to better predict inertial particle concentration (Innocenti et al., 2016), but has not been investigated in LES-based airway deposition modelling. Additionally, such a model is currently not available in OpenFOAM. Our future study will investigate the effect of turbulent dispersion on drug deposition in patient-specific airways.

We softened the particles to increase the DEM timestep and lower the computational cost. Particle softening is standard in DEM simulations to permit a larger DEM timestep as the particle's collision happens over a longer period due to a lower stiffness. We mitigate an impact of increased van der Waals forces by including the cohesion model of Gu et al. (2016a). This model makes particle cohesion independent of softened particle stiffness, and therefore increases our simulation timestep from $t_{\text{DEM}} = 0.8 \text{ ns}$ to 25 ns for $d_p = 10 \mu\text{m}$. This reduction of real particle stiffness (k_R) to a softer stiffness (k_S) has been shown to have negligible effect on fluid hydrodynamics and particle cohesion (Gu et al., 2016a; Ozel et al., 2017). For dry-powder inhalers, where the particle transport is primarily dependent on cohesion, Gu et al. (2016a)'s model may not be applicable. However, this is not the case for the mildly cohesive particles modelled in this study (Gu et al., 2016a). The use of this model therefore makes the effect of softening particles negligible in our simulations. This allows us to use DEM to model inhaler particle-particle and particle-wall interactions with feasible computation times.

5. Conclusion

We have performed patient-specific inhaler deposition simulations across three diverse patients during exacerbating inhalation conditions compared to a healthy breathing profile. Our results showed that during an exacerbation less of the drug reaches the deep lung for 10 and $4 \mu\text{m}$ particles. For $10 \mu\text{m}$ particles, the total upper airway varied strongly with inhalation, but the change was small for $4 \mu\text{m}$ particles. The ratio of drug in the lower lobes to upper lobes of the lung was 35% larger during healthy inhalation than an exacerbation, showing enhanced asymmetry during slower inhalation. For both particle sizes the size, location and intensity of local deposition hotspots varied with patient inhalation and airway shape. This demonstrates that image-based models are needed to predict therapeutic outcome in respiratory CPFD studies. Image-based models should be combined with inhalation profiles that represent various symptoms such as an exacerbation to optimise patient treatments.

585 Acknowledgements

For their early involvement and insight into the issue faced by patients, the authors would like to thank Elisabeth Ehrlich and Olivia Fulton. Also Carol Porteous (Patient Public Involvement Advisor) who arranged our contact.

The authors thank Prof. Vicki Stone from Heriot-Watt University for fruitful discussions.
590 The authors also thank Dr Filippo Coletti from University of Minnesota for providing the surface file of the healthy patient's segmented airways that enabled our model validation and was used to compare deposition across the patients. AO thanks Prof. Sankaran Sundaresan from Princeton University for his support and fruitful discussions. JW thanks Dr Rudolf Hellmuth from Vascular Flow Technologies for fruitful discussions.

595 JW was funded by an Institution of Mechanical Engineers Postgraduate Masters Scholarship 2018, a Scottish Funding Council Masters fee scholarship 2018, and a Carnegie-Trust for the Universities of Scotland PhD scholarship 2019.

6. Conflict of Interest

The authors declare that they have no known competing financial interests or personal
600 relationships that could have appeared to influence the work reported in this paper.

Appendix A. Gas and solid-phase modelling

Simulations in this study solve fluid transport through the respiratory system on a Eulerian grid with Lagrangian particle tracking using the discrete element method (DEM). We solve the volume-filtered mass (A.1) and momentum (A.2) balance equations at each finite-
605 volume cell. Here they are presented in terms of the volume-filtered variables, accounting for particle interactions as derived by Anderson and Jackson (1967) and Capecelatro and Desjardins (2013), with overbars denoting filtered terms and bold, lower- and upper-case characters describing vectors and second order tensors, respectively,

$$\frac{\partial}{\partial t}(1 - \phi) + \nabla \cdot [(1 - \phi)\bar{\mathbf{u}}] = 0, \quad (\text{A.1})$$

$$\rho_f(1 - \phi) \left(\frac{\partial \bar{\mathbf{u}}}{\partial t} + \bar{\mathbf{u}} \cdot \nabla \bar{\mathbf{u}} \right) = \nabla \cdot (\bar{\boldsymbol{\tau}} - \mathbf{R}_u) + \boldsymbol{\Phi}_d + \rho_f(1 - \phi)\mathbf{g}, \quad (\text{A.2})$$

there $\bar{\mathbf{u}}$ is the filtered local velocity vector, \bar{p} is the filtered local fluid-pressure, ρ_f is the fluid
 610 density, ϕ is the particle volume fraction, \mathbf{g} is gravitational acceleration (direction shown
 in Figure 5), the force caused by interaction with the discrete phase is $-\Phi_d$, \mathbf{R}_u is the sub-
 grid stress from filtering, modelled using a dynamic Smagorinsky model (described in Sec-
 tion 2.2). $\bar{\boldsymbol{\tau}}$ is the filtered fluid stress tensor, composed of the fluid pressure gradient ($\nabla \bar{p}$),
 the deviatoric viscous stress tensor (labelled below), and an additional term arising from
 615 filtering of sub-grid velocity fluctuations (\mathbf{R}_μ) (Capecelatro and Desjardins, 2013)

$$\bar{\boldsymbol{\tau}} = \nabla \bar{p} + \underbrace{\mu_f \left[\nabla \bar{\mathbf{u}} + \nabla \bar{\mathbf{u}}^T - \frac{2}{3} (\nabla \cdot \bar{\mathbf{u}}) \mathbf{I} \right]}_{\text{deviatoric viscous stress tensor}} + \mathbf{R}_\mu, \quad (\text{A.3})$$

where \mathbf{I} is an identity tensor and \mathbf{R}_μ is the term arising from filtering velocity gradients. In
 this study we dismissed \mathbf{R}_μ to be included in a later study, and the deviatoric part of the
 stress tensor due to its minor influence on gas-solid flows in comparison to \mathbf{R}_u (Agrawal
 et al., 2001). Φ_d is dependent on the interaction force between particles and fluid ($\mathbf{f}_{f \rightarrow p,i}$) of
 620 all particles within a cell volume ($\mathcal{V}_{\text{cell}}$) by, $\Phi_d = -\frac{\sum_i^{N_p} \mathbf{f}_{f \rightarrow p,i}}{\mathcal{V}_{\text{cell}}}$ (Anderson and Jackson, 1967;
 Capecelatro and Desjardins, 2013; Ozel et al., 2017). For a particle i , this is related to the
 filtered fluid stresses and the particle's drag by $\mathbf{f}_{f \rightarrow p,i} = \mathcal{V}_i \nabla \cdot \bar{\boldsymbol{\tau}} + \mathbf{f}_{d,i}$, where $\mathbf{f}_{d,i}$ is the drag
 force, taken from Beetstra et al. (2007).

Newton's equations of motion are used to track particle linear motion (A.4) and angular
 625 motion (A.5) (Cundall and Strack, 1979; Capecelatro and Desjardins, 2013), by

$$m_i \frac{d\mathbf{v}_i}{dt} = \sum_j (\mathbf{f}_{c,ij}^n + \mathbf{f}_{c,ij}^t) + \sum_w (\mathbf{f}_{c,iw}^n + \mathbf{f}_{c,iw}^t) + \sum_k \mathbf{f}_{v,ik} + \mathbf{f}_{f \rightarrow p,i} + m_i \mathbf{g} \quad (\text{A.4})$$

$$I_i \frac{d\boldsymbol{\omega}_i}{dt} = \sum_j (\mathbf{n} \times \mathbf{f}_{c,ij}^t), \quad (\text{A.5})$$

where m_i is the mass of a particle, i , v and ω are the particle's translational and angular
 velocity, respectively, \mathbf{f}_c is the contact force from a particle-particle collision (subscript ij),
 and particle-wall collision (subscript iw), in the normal and tangential directions shown by
 sub or superscript n and t , respectively. van der Waals forces are shown with $(.)_v$. Angular
 630 momentum (A.5) from inter-particle collisions depends on outward unit normal vector from
 particle centre to the point of collision, \mathbf{n} , and the tangential contact force $\mathbf{f}_{c,ij}^t$. Particle

contact forces are solved here using a linear spring-dashpot model (Cundall and Strack, 1979; Capecelatro and Desjardins, 2013),

$$\mathbf{f}_{c,ij}^n = k_n + \delta_n \mathbf{n}_{ij} - \gamma_n m^* \mathbf{v}_{ij}^n, \quad (\text{A.6})$$

$$\mathbf{f}_{c,ij}^t = \begin{cases} k_t \mathbf{t}_{ij} - \gamma_t m^* \mathbf{v}_{ij}^t & \text{for } |\mathbf{f}_{c,ij}^t| < \mu_s |\mathbf{f}_{c,ij}^n|, \\ -\mu_s |\mathbf{f}_{c,ij}^n| \frac{\mathbf{t}_{ij}}{|\mathbf{t}_{ij}|} & \text{for } |\mathbf{f}_{c,ij}^t| \geq \mu_s |\mathbf{f}_{c,ij}^n|, \end{cases} \quad (\text{A.7})$$

where k , is the particle's spring constant with $k_t = 2k_n/7$ (Matuttis et al., 2000), δ is the
635 particle overlap distance, γ is the viscous damping coefficient. γ_n is calculated from the
coefficient of restitution $e = \exp(\gamma_n \pi / \sqrt{4k_n/m^* - \gamma_n^2})$ (Gu et al., 2016b). $\gamma_t = 2\gamma_n/7$. Effective
particle mass is $m^* = m_i m_j / (m_i + m_j)$, in particle-wall collisions $m^* = m_i$, as one radius
is assumed infinite (Gu et al., 2016a); μ_s is the sliding coefficient; \mathbf{t}_{ij} represents the tangential
displacement due to a collision, found from the integral of its velocity component.

640 References

- Agrawal, K., Loezos, P. N., Syamlal, M. and Sundaresan, S. (2001), 'The role of meso-scale
structures in rapid gas–solid flows', *Journal of Fluid Mechanics* **445**, 151–185.
- Anderson, T. B. and Jackson, R. (1967), 'Fluid mechanical description of fluidized beds. equa-
tions of motion', *Industrial & Engineering Chemistry Fundamentals* **6**(4), 527–539.
- 645 Anjilvel, S. and Asgharian, B. (1995), 'A multiple-path model of particle deposition in the rat
lung', *Fundamental and Applied Toxicology* **28**(1), 41–50.
- Asgharian, B., Hofmann, W. and Bergmann, R. (2001), 'Particle deposition in a multiple-path
model of the human lung', *Aerosol Science & Technology* **34**(4), 332–339.
- Aykac, D., Hoffman, E. A., McLennan, G. and Reinhardt, J. M. (2003), 'Segmentation and
650 analysis of the human airway tree from three-dimensional X-ray CT images', *IEEE trans-
actions on medical imaging* **22**(8), 940–950.
- Balashazy, I., Hofmann, W. and Heistracher, T. (1999), 'Computation of local enhancement
factors for the quantification of particle deposition patterns in airway bifurcations', *Journal
of Aerosol Science* **30**(2), 185–203.

- 655 Banko, A., Coletti, F., Schiavazzi, D., Elkins, C. and Eaton, J. (2015), 'Three-dimensional inspiratory flow in the upper and central human airways', *Experiments in Fluids* **56**(6), 117.
- Barbu, C., Iordache, M. and Man, M. (2011), 'Inflammation in COPD: pathogenesis, local and systemic effects', *Rom J Morphol Embryol* **52**(1), 21–27.
- Bates, A., Cetto, R., Doorly, D., Schroter, R., Tolley, N. and Comerford, A. (2016), 'The effects of curvature and constriction on airflow and energy loss in pathological tracheas',
660 *Respiratory physiology & neurobiology* **234**, 69–78.
- Beetstra, R., van der Hoef, M. A. and Kuipers, J. (2007), 'Drag force of intermediate reynolds number flow past mono-and bidisperse arrays of spheres', *AIChE journal* **53**(2), 489–501.
- Behnaz, A. S., Snider, J., Chibuzor, E., Esposito, G., Wilson, E., Yaniv, Z., Cohen, E. and
665 Cleary, K. (2010), Quantitative ct for volumetric analysis of medical images: initial results for liver tumors, in 'Medical Imaging 2010: Image Processing', Vol. 7623, International Society for Optics and Photonics, p. 76233U.
- Bernardini, M. (2014), 'Reynolds number scaling of inertial particle statistics in turbulent channel flows', *Journal of Fluid Mechanics* **758**.
- 670 Borghardt, J. M., Weber, B., Staab, A. and Kloft, C. (2015), 'Pharmacometric models for characterizing the pharmacokinetics of orally inhaled drugs', *The AAPS journal* **17**(4), 853–870.
- Capecelatro, J. and Desjardins, O. (2013), 'An euler-lagrange strategy for simulating particle-laden flows', *Journal of Computational Physics* **238**, 1–31.
- Chen, X., Zhong, W., Zhou, X., Jin, B. and Sun, B. (2012), 'CFD–DEM simulation of particle
675 transport and deposition in pulmonary airway', *Powder Technology* **228**, 309–318.
- Chevreur, K., Brigham, K. B., Michel, M., Rault, G. and Network, B.-R. R. (2015), 'Costs and health-related quality of life of patients with cystic fibrosis and their carers in france', *Journal of Cystic Fibrosis* **14**(3), 384–391.
- Clark, A. (1995), 'Medical aerosol inhalers: past, present, and future', *Aerosol science and
680 technology* **22**(4), 374–391.

- Clark, K., Vendt, B., Smith, K., Freymann, J., Kirby, J., Koppel, P., Moore, S., Phillips, S., Maffitt, D., Pringle, M. et al. (2013), 'The Cancer Imaging Archive (TCIA): maintaining and operating a public information repository', *Journal of digital imaging* **26**(6), 1045–1057.
- Colasanti, R. L., Morris, M. J., Madgwick, R. G., Sutton, L. and Williams, E. M. (2004), 'Analysis of tidal breathing profiles in cystic fibrosis and COPD', *Chest* **125**(3), 901–908.
- Cundall, P. A. and Strack, O. D. (1979), 'A discrete numerical model for granular assemblies', *Geotechnique* **29**(1), 47–65.
- Darquenne, C., Fleming, J. S., Katz, I., Martin, A. R., Schroeter, J., Usmani, O. S., Venegas, J. and Schmid, O. (2016), 'Bridging the gap between science and clinical efficacy: physiology, imaging, and modeling of aerosols in the lung', *Journal of aerosol medicine and pulmonary drug delivery* **29**(2), 107–126.
- Das, P., Nof, E., Amirav, I., Kassinos, S. C. and Sznitman, J. (2018), 'Targeting inhaled aerosol delivery to upper airways in children: Insight from computational fluid dynamics (cfD)', *PloS one* **13**(11), e0207711.
- De Nunzio, G., Tommasi, E., Agrusti, A., Cataldo, R., De Mitri, I., Favetta, M., Maglio, S., Massafra, A., Quarta, M., Torsello, M. et al. (2011), 'Automatic lung segmentation in CT images with accurate handling of the hilar region', *Journal of digital imaging* **24**(1), 11–27.
- Deng, Q., Ou, C., Chen, J. and Xiang, Y. (2018), 'Particle deposition in tracheobronchial airways of an infant, child and adult', *Science of the Total Environment* **612**, 339–346.
- Dockrell, M., Partridge, M. and Valovirta, E. (2007), 'The limitations of severe asthma: the results of a european survey', *Allergy* **62**(2), 134–141.
- Dolovich, M. (1991), 'Measurement of particle size characteristics of metered dose inhaler (MDI) aerosols', *Journal of Aerosol Medicine* **4**(3), 251–263.
- Dong, J., Tian, L. and Ahmadi, G. (2019), 'Numerical assessment of respiratory airway exposure risks to diesel exhaust particles', *Experimental and Computational Multiphase Flow* **1**(1), 51–59.

- Duan, H.-H., Su, G.-Q., Huang, Y.-C., Song, L.-T. and Nie, S.-D. (2019), 'Segmentation of pulmonary vascular tree by incorporating vessel enhancement filter and variational region-growing', *Journal of X-ray science and technology* **27**(2), 343–360.
- 710 Engstrom, J. D., Tam, J. M., Miller, M. A., Williams, R. O. and Johnston, K. P. (2009), 'Templated open flocs of nanorods for enhanced pulmonary delivery with pressurized metered dose inhalers', *Pharmaceutical research* **26**(1), 101–117.
- Fedorov, A., Beichel, R., Kalpathy-Cramer, J., Finet, J., Fillion-Robin, J.-C., Pujol, S., Bauer, C., Jennings, D., Fennessy, F., Sonka, M. et al. (2012), '3d slicer as an image computing
715 platform for the quantitative imaging network', *Magnetic resonance imaging* **30**(9), 1323–1341.
- Feng, Y., Zhao, J., Kleinstreuer, C., Wang, Q., Wang, J., Wu, D. H. and Lin, J. (2018), 'An in silico inter-subject variability study of extra-thoracic morphology effects on inhaled particle transport and deposition', *Journal of Aerosol Science* **123**, 185–207.
- 720 Germano, M., Piomelli, U., Moin, P. and Cabot, W. H. (1991), 'A dynamic subgrid-scale eddy viscosity model', *Physics of Fluids A: Fluid Dynamics* **3**(7), 1760–1765.
- Gruffydd-Jones, K., Thomas, M., Roman-Rodríguez, M., Infantino, A., FitzGerald, J. M., Pavord, I., Haddon, J. M., Elsasser, U. and Vogelberg, C. (2019), 'Asthma impacts on workplace productivity in employed patients who are symptomatic despite background therapy: a multinational survey', *Journal of asthma and allergy* **12**, 183.
725
- Gu, Y., Ozel, A., Kolehmainen, J. and Sundaresan, S. (2019), 'Computationally generated constitutive models for particle phase rheology in gas-fluidized suspensions', *Journal of Fluid Mechanics* **860**, 318–349.
- Gu, Y., Ozel, A. and Sundaresan, S. (2016a), 'A modified cohesion model for CFD–DEM
730 simulations of fluidization', *Powder technology* **296**, 17–28.
- Gu, Y., Ozel, A. and Sundaresan, S. (2016b), 'Rheology of granular materials with size distributions across dense-flow regimes', *Powder technology* **295**, 322–329.

- Hamaker, H. (1937), 'The london—van der waals attraction between spherical particles', *physica* **4**(10), 1058–1072.
- 735 Holbrook, L. T. and Longest, P. W. (2013), 'Validating cfd predictions of highly localized aerosol deposition in airway models: In vitro data and effects of surface properties', *Journal of Aerosol Science* **59**, 6–21.
- Innocenti, A., Marchioli, C. and Chibbaro, S. (2016), 'Lagrangian filtered density function for LES-based stochastic modelling of turbulent particle-laden flows', *Physics of Fluids*
740 **28**(11), 115106.
- Inthavong, K., Choi, L.-T., Tu, J., Ding, S. and Thien, F. (2010), 'Micron particle deposition in a tracheobronchial airway model under different breathing conditions', *Medical engineering & physics* **32**(10), 1198–1212.
- Islam, M. S., Paul, G., Ong, H. X., Young, P. M., Gu, Y. and Saha, S. C. (2020), 'A review
745 of respiratory anatomical development, air flow characterization and particle deposition', *International Journal of Environmental Research and Public Health* **17**(2), 380.
- Jan, M. A., Marshall, I. and Douglas, N. J. (1994), 'Effect of posture on upper airway dimensions in normal human.', *American Journal of Respiratory and Critical Care Medicine* **149**(1), 145–148.
- 750 Jin, H., Fan, J., Zeng, M. and Cen, K. (2007), 'Large eddy simulation of inhaled particle deposition within the human upper respiratory tract', *Journal of Aerosol Science* **38**(3), 257–268.
- Ju, D., Shrimpton, J. and Hearn, A. (2010), 'The effect of reduction of propellant mass fraction on the injection profile of metered dose inhalers', *International journal of pharmaceuticals*
755 **391**(1-2), 221–229.
- Katsaounou, P., Odemyr, M., Spranger, O., Hyland, M. E., Kroegel, C., Conde, L. G., Gore, R., Menzella, F., Ribas, C. D., Morais-Almeida, M. et al. (2018), 'Still fighting for breath: a patient survey of the challenges and impact of severe asthma', *ERJ open research* **4**(4), 00076–2018.

- 760 Khajeh-Hosseini-Dalasm, N. and Longest, P. W. (2015), 'Deposition of particles in the alveolar airways: inhalation and breath-hold with pharmaceutical aerosols', *Journal of aerosol science* **79**, 15–30.
- Kleinstreuer, C., Shi, H. and Zhang, Z. (2007), 'Computational analyses of a pressurized metered dose inhaler and a new drug-aerosol targeting methodology', *Journal of Aerosol Medicine* **20**(3), 294–309. PMID: 17894536.
765 **URL:** <https://doi.org/10.1089/jam.2006.0617>
- Kleinstreuer, C. and Zhang, Z. (2003), 'Targeted drug aerosol deposition analysis for a four-generation lung airway model with hemispherical tumors', *Transactions-American Society of Mechanical Engineers Journal of Biomechanical Engineering* **125**(2), 197–206.
- 770 Kleinstreuer, C. and Zhang, Z. (2010), 'Airflow and particle transport in the human respiratory system', *Annual review of fluid mechanics* **42**, 301–334.
- Kloss, C. and Goniva, C. (2011), 'LIGGGHTS–open source discrete element simulations of granular materials based on LAMMPS', *Supplemental Proceedings: Materials Fabrication, Properties, Characterization, and Modeling* **2**, 781–788.
- 775 Kloss, C., Goniva, C., Hager, A., Amberger, S. and Pirker, S. (2012), 'Models, algorithms and validation for opensource DEM and CFD–DEM', *Progress in Computational Fluid Dynamics, an International Journal* **12**(2-3), 140–152.
- Koullapis, P., Ollson, B., Kassinos, S. C. and Sznitman, J. (2019), 'Multiscale in silico lung modeling strategies for aerosol inhalation therapy and drug delivery', *Current Opinion in Biomedical Engineering* .
780
- Kuprat, A., Jalali, M., Jan, T., Corley, R., Asgharian, B., Price, O., Singh, R., Colby, S. and Darquenne, C. (2020), 'Efficient bi-directional coupling of 3d computational fluid-particle dynamics and 1d multiple path particle dosimetry lung models for multiscale modeling of aerosol dosimetry', *Journal of Aerosol Science* p. 105647.
- 785 Lambert, A. R., O'shaughnessy, P. T., Tawhai, M. H., Hoffman, E. A. and Lin, C.-L. (2011), 'Regional deposition of particles in an image-based airway model: large-eddy simulation and left-right lung ventilation asymmetry', *Aerosol Science and Technology* **45**(1), 11–25.

- Legendre, D., Daniel, C. and Guiraud, P. (2005), 'Experimental study of a drop bouncing on a wall in a liquid', *Physics of Fluids* **17**(9), 097105.
- 790 Legendre, D., Zenit, R., Daniel, C. and Guiraud, P. (2006), 'A note on the modelling of the bouncing of spherical drops or solid spheres on a wall in viscous fluid', *Chemical engineering science* **61**(11), 3543–3549.
- Lilly, D. K. (1992), 'A proposed modification of the germano subgrid-scale closure method', *Physics of Fluids A: Fluid Dynamics* **4**(3), 633–635.
- 795 Longest, P. W., Hindle, M., Choudhuri, S. D. and Xi, J. (2008), 'Comparison of ambient and spray aerosol deposition in a standard induction port and more realistic mouth–throat geometry', *Journal of Aerosol Science* **39**(7), 572–591.
- Longest, P. W., Tian, G., Walenga, R. L. and Hindle, M. (2012), 'Comparing mdi and dpi aerosol deposition using in vitro experiments and a new stochastic individual path (sip) model of the conducting airways', *Pharmaceutical research* **29**(6), 1670–1688.
- 800 Longest, P. W., Vinchurkar, S. and Martonen, T. (2006), 'Transport and deposition of respiratory aerosols in models of childhood asthma', *Journal of Aerosol Science* **37**(10), 1234–1257.
- Lu, D., Lee, S. L., Lionberger, R. A., Choi, S., Adams, W., Caramenico, H. N., Chowdhury, B. A., Conner, D. P., Katial, R., Limb, S. et al. (2015), 'International guidelines for bioequivalence of locally acting orally inhaled drug products: similarities and differences',
805 *The AAPS journal* **17**(3), 546–557.
- Ma, B. and Lutchen, K. R. (2006), 'An anatomically based hybrid computational model of the human lung and its application to low frequency oscillatory mechanics', *Annals of biomedical engineering* **34**(11), 1691–1704.
- 810 Marchioli, C., Salvetti, M. V. and Soldati, A. (2008), 'Some issues concerning large-eddy simulation of inertial particle dispersion in turbulent bounded flows', *Physics of Fluids* **20**(4), 040603.

- Matuttis, H., Luding, S. and Herrmann, H. (2000), 'Discrete element simulations of dense packings and heaps made of spherical and non-spherical particles', *Powder technology* **109**(1-3), 278–292.
- Mayer, D., Bartz, D., Fischer, J., Ley, S., del Rio, A., Thust, S., Kauczor, H. U. and Heussel, C. P. (2004), 'Hybrid segmentation and virtual bronchoscopy based on CT images', *Academic Radiology* **11**(5), 551–565.
- McQuaid, E. L., Kopel, S. J., Klein, R. B. and Fritz, G. K. (2003), 'Medication adherence in pediatric asthma: reasoning, responsibility, and behavior', *Journal of pediatric psychology* **28**(5), 323–333.
- Mexichem (n.d.), 'Zephex®134a', Website <http://www.mexichemfluor.com/products/medical/zephex>. Accessed 14/05/2019.
URL: <http://www.mexichemfluor.com/products/medical/zephex134a/>
- Mitchell, J. P., Nagel, M. W., Wiersema, K. J. and Doyle, C. C. (2003), 'Aerodynamic particle size analysis of aerosols from pressurized metered-dose inhalers: comparison of andersen 8-stage cascade impactor, next generation pharmaceutical impactor, and model 3321 aerodynamic particle sizer aerosol spectrometer', *AAPS PharmSciTech* **4**(4), 425–433.
- Miyawaki, S., Tawhai, M. H., Hoffman, E. A. and Lin, C.-L. (2012), 'Effect of carrier gas properties on aerosol distribution in a CT-based human airway numerical model', *Annals of biomedical engineering* **40**(7), 1495–1507.
- Nardelli, P., Khan, K. A., Corvò, A., Moore, N., Murphy, M. J., Twomey, M., O'Connor, O. J., Kennedy, M. P., Estépar, R. S. J., Maher, M. M. et al. (2015), 'Optimizing parameters of an open-source airway segmentation algorithm using different CT images', *Biomedical engineering online* **14**(1), 62.
- Naseri, A., Shaghaghian, S., Abouali, O. and Ahmadi, G. (2017), 'Numerical investigation of transient transport and deposition of microparticles under unsteady inspiratory flow in human upper airways', *Respiratory physiology & neurobiology* **244**, 56–72.

- Newman, S. P. (2005), 'Principles of metered-dose inhaler design', *Respiratory Care* 50(9), 1177–1190.
URL: <http://rc.rcjournal.com/content/50/9/1177>
- Nunes, C., Pereira, A. M. and Morais-Almeida, M. (2017), 'Asthma costs and social impact', *Asthma Research and Practice* 3(1), 1.
- Oakes, J. M., Roth, S. C. and Shadden, S. C. (2018), 'Airflow simulations in infant, child, and adult pulmonary conducting airways', *Annals of biomedical engineering* 46(3), 498–512.
- Olsson, B. and Bäckman, P. (2018), Mimetikos preludium™: A new pharma-friendly aerosol drug deposition calculator, in 'Respiratory Drug Delivery'.
- Olsson, B., Bondesson, E., Borgström, L., Edsbäcker, S., Eirefelt, S., Ekelund, K., Gustavsson, L. and Hegelund-Myrbäck, T. (2011), Pulmonary drug metabolism, clearance, and absorption, in 'Controlled pulmonary drug delivery', Springer, pp. 21–50.
- Ozel, A., Gu, Y., Milioli, C. C., Kolehmainen, J. and Sundaresan, S. (2017), 'Towards filtered drag force model for non-cohesive and cohesive particle-gas flows', *Physics of Fluids* 29(10), 103308.
- Ozel, A., Kolehmainen, J., Radl, S. and Sundaresan, S. (2016), 'Fluid and particle coarsening of drag force for discrete-parcel approach', *Chemical engineering science* 155, 258–267.
- Poorbahrami, K., Mummy, D. G., Fain, S. B. and Oakes, J. M. (2019), 'Patient-specific modeling of aerosol delivery in healthy and asthmatic adults', *Journal of Applied Physiology*.
- Poorbahrami, K. and Oakes, J. M. (2019), 'Regional flow and deposition variability in adult female lungs: A numerical simulation pilot study', *Clinical Biomechanics* 66, 40–49.
- Radl, S. and Sundaresan, S. (2014), 'A drag model for filtered euler-lagrange simulations of clustered gas-particle suspensions', *Chemical engineering science* 117, 416–425.
- Ring, N., Booth, H., Wilson, C., Hoskins, G., Pinnock, H., Sheikh, A. and Jepson, R. (2015), 'The 'vicious cycle' of personalised asthma action plan implementation in primary care: a qualitative study of patients and health professionals' views', *BMC family practice* 16(1), 145.

- Robinson, R. J., Snyder, P. and Oldham, M. J. (2007), 'Comparison of particle tracking algorithms in commercial CFD packages: sedimentation and diffusion', *Inhalation toxicology* **19**(6-7), 517–531.
- Rubin, B. K. (2007), 'Mucus structure and properties in cystic fibrosis', *Paediatric respiratory reviews* **8**(1), 4–7.
- Sagaut, P. (2006), *Large eddy simulation for incompressible flows: an introduction*, Springer Science & Business Media.
- Sen, Y., Zhang, Y., Qian, Y. and Morgan, M. (2011), A comparison of medical image segmentation methods for cerebral aneurysm computational hemodynamics, in '2011 4th International Conference on Biomedical Engineering and Informatics (BMEI)', Vol. 2, IEEE, pp. 901–904.
- Smagorinsky, J. (1963), 'General circulation experiments with the primitive equations: I. the basic experiment', *Monthly weather review* **91**(3), 99–164.
- Solomon, P. A., Gehr, P., Bennett, D. H., Phalen, R. F., Méndez, L. B., Rothen-Rutishauser, B., Clift, M., Brandenberger, C. and Mühlfeld, C. (2012), 'Macroscopic to microscopic scales of particle dosimetry: from source to fate in the body', *Air Quality, Atmosphere & Health* **5**(2), 169–187.
- Squires, K. D. and Eaton, J. K. (1991), 'Preferential concentration of particles by turbulence', *Physics of Fluids A: Fluid Dynamics* **3**(5), 1169–1178.
- Sundaresan, S., Ozel, A. and Kolehmainen, J. (2018), 'Toward constitutive models for momentum, species, and energy transport in gas–particle flows', *Annual review of chemical and biomolecular engineering* **9**, 61–81.
- Tatsumura, T., Koyama, S., Tsujimoto, M., Kitagawa, M. and Kagamimori, S. (1993), 'Further study of nebulisation chemotherapy, a new chemotherapeutic method in the treatment of lung carcinomas: fundamental and clinical', *British journal of cancer* **68**(6), 1146.
- The Global Asthma Network (2018), 'The Global Asthma Report'.

- Usmani, O. S. (2019), 'Choosing the right inhaler for your asthma or COPD patient', *Therapeutics and clinical risk management* **15**, 461.
- Usmani, O. S., Biddiscombe, M. F. and Barnes, P. J. (2005), 'Regional lung deposition and
895 bronchodilator response as a function of β 2-agonist particle size', *American journal of respiratory and critical care medicine* **172**(12), 1497–1504.
- Usmani, O. S., Biddiscombe, M. F., Nightingale, J. A., Underwood, S. R. and Barnes, P. J. (2003), 'Effects of bronchodilator particle size in asthmatic patients using monodisperse aerosols', *Journal of Applied Physiology* **95**(5), 2106–2112.
- 900 van Holsbeke, C., De Backer, J., Vos, W. and Marshall, J. (2018), 'Use of functional respiratory imaging to characterize the effect of inhalation profile and particle size on lung deposition of inhaled corticosteroid/long-acting β 2-agonists delivered via a pressurized metered-dose inhaler', *Therapeutic advances in respiratory disease* **12**, 1753466618760948.
- van Wachem, B., Curran, T. and Evrard, F. (2020), 'Fully correlated stochastic inter-particle
905 collision model for euler-lagrange gas-solid flows', *Flow, Turbulence and Combustion* **105**(4), 935–963.
- Verlet, L. (1967), 'Computer "experiments" on classical fluids. i. thermodynamical properties of lennard-jones molecules', *Physical review* **159**(1), 98.
- Wang, Y., Chu, K. and Yu, A. (2017), Transport and deposition of cohesive pharmaceutical
910 powders in human airway, in 'EPJ Web of Conferences', Vol. 140, EDP Sciences, p. 08004.
- Wei, W., Huang, S.-w., Chen, L.-h., Qi, Y., Qiu, Y.-m. and Li, S.-t. (2017), 'Airflow behavior changes in upper airway caused by different head and neck positions: Comparison by computational fluid dynamics', *Journal of biomechanics* **52**, 89–94.
- Weller, H. G., Tabor, G., Jasak, H. and Fureby, C. (1998), 'A tensorial approach to com-
915 putational continuum mechanics using object-oriented techniques', *Computers in physics* **12**(6), 620–631.

- Williams, J., Kolehmainen, J., Stone, V., Cunningham, S., Ozel, A. and Wolfram, U. (2021),
Evaluating aerosol drug deposition during exacerbation and healthy breathing using
medical image-based models, *in* 'Respiratory Drug Delivery', Vol. 1, pp. 171–174.
- 920 Wittgen, B. P., Kunst, P. W., Van Der Born, K., Van Wijk, A. W., Perkins, W., Pilkiewicz, F. G.,
Perez-Soler, R., Nicholson, S., Peters, G. J. and Postmus, P. E. (2007), 'Phase i study of
aerosolized slit cisplatin in the treatment of patients with carcinoma of the lung', *Clinical
cancer research* **13**(8), 2414–2421.
- Xi, J., Berlinski, A., Zhou, Y., Greenberg, B. and Ou, X. (2012), 'Breathing resistance and
925 ultrafine particle deposition in nasal–laryngeal airways of a newborn, an infant, a child,
and an adult', *Annals of biomedical engineering* **40**(12), 2579–2595.
- Xi, J., Si, X., Kim, J. W. and Berlinski, A. (2011), 'Simulation of airflow and aerosol deposition
in the nasal cavity of a 5-year-old child', *Journal of Aerosol Science* **42**(3), 156–173.
- Yang, J., Sharp, G., Veeraraghavan, H., van Elmpt, W., Dekker, A., Lustberg, T. and Gooding,
930 M. (2017), 'Dataset from lung CT segmentation challenge', *The Cancer Imaging Archive* .
- Yang, J., Veeraraghavan, H., Armato III, S. G., Farahani, K., Kirby, J. S., Kalpathy-Kramer,
J., van Elmpt, W., Dekker, A., Han, X., Feng, X. et al. (2018), 'Autosegmentation for tho-
racic radiation treatment planning: A grand challenge at AAPM 2017', *Medical physics*
45(10), 4568–4581.
- 935 Zhang, B., Qi, S., Yue, Y., Shen, J., Li, C., Qian, W. and Wu, J. (2018), 'Particle Disposition in
the Realistic Airway Tree Models of Subjects with Tracheal Bronchus and COPD', *BioMed
research international* **2018**.
- Zhang, Z., Kleinstreuer, C. and Hyun, S. (2012), 'Size-change and deposition of conven-
tional and composite cigarette smoke particles during inhalation in a subject-specific air-
940 way model', *Journal of Aerosol Science* **46**, 34–52.
- Zhang, Z., Kleinstreuer, C. and Kim, C. S. (2009), 'Comparison of analytical and cfd mod-
els with regard to micron particle deposition in a human 16-generation tracheobronchial
airway model', *Journal of Aerosol Science* **40**(1), 16–28.